Session 3: How to use VICH GLs VICH5 Conference, October 2015, Tokyo 1.

Slides:



Advertisements
Similar presentations
EPAA Annual conference November Regulatory acceptance of alternative approaches for pharmaceuticals Jean-Marc Vidal Safety & Efficacy of Human Medicines.
Advertisements

Foundations of Regulation
Merton V. Smith, Ph.D., J.D. Director International Programs Center for Veterinary Medicine U.S. Food and Drug Administration Governance of Veterinary.
The United States Experience Implementing the WTO SPS Agreement Hangzhou, China December 2008 Roseanne Freese Senior WTO SPS Affairs Officer United States.
Safeguarding Animal Health 1 Proposed BSE Comprehensive Rule: A New Approach to BSE Rulemaking Dr. Christopher Robinson Assistant Director, NCIE BSE Comprehensive.
Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
Pharma.be The Initiative to Promote Clinical Trials in Belgium Key Performance Indicators: Impact on Clinical Research of European Legislation Square –
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Prequalification programme: Priority essential.
Overview of ICH Procedures July 2015
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
The Aarhus & Espoo Conventions Making implementation work for stakeholders.
IAEA International Atomic Energy Agency Overview of legal framework Regional Workshop - School for Drafting Regulations 3-14 November 2014 Abdelmadjid.
Support for the Modernisation of the Mongolian Standardisation system – EuropeAid/134305/C/SER/MN Training on standardisation Support to the Modernisation.
*The views expressed in this presentation are those of the presenter’s and do not necessarily represent the views of the U.S. Food and Drug Administration.
Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:
FDA Public Meeting Preparation for the ICH Meetings in Tokyo, Japan, Including Progress on the Common Technical Document and Possibilities for New Topics.
© International Training Centre of the ILO Training Centre of the ILO 1 International Labour Standards (ILS) and their.
ICH Quality Topics Update
Future needs for capacity building and recommendations to the OIE Dr Sarah Kahn Consultant to the OIE
Tripartite Declaration of Principles concerning Multinational Enterprises and Social Policy (MNE Declaration) Multinational enterprises and social policy.
Special Meeting on Procedures for Information Exchange November 7, 2007 Geneva Session 1 Anne Meininger United States USA WTO TBT Enquiry Point.
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
Application of VICH GLs – extract from group discussion General: VICH GLs do not prescribe the data package to be submitted for registration, they merely.
1 Outcome of the 4 th Global Animal Health Conference (GAHC) June 2015 Bettye K. Walters, DVM US Food and Drug Administration
JMAFF (Chair of Biologicals Quality Monitoring EWG)
VICH General Principles and current update of VICH Outreach Forum activity 1.
VICH Training Strategy Steven D. Vaughn, DVM Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine U.S. Food and Drug Administration.
Introduction to the VICH Outreach Forum Steven D. Vaughn, DVM VICH Workshop Dar Es Salaam, Tanzania – June 24, 2015.
GLP/GCP: Requirement and implementation (Japan) Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan 1 5 th VICH Outreach.
-What is VICH, History and Objectives Hervé MARION, DVM VICH Secretariat.
1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.
An agency of the European Union Principles for the assessment and authorisation of antimicrobials in the EU VICH Outreach Forum, October 2015 Presented.
The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.
Workshop on “EU Enlargement: Regulatory Convergence in Non-acceding Countries” Athens 7 – 8 November 2003 Regulatory Convergence and Technical Standards.
Session 5: 3Rs statement VICH5 Conference, October 2015, Tokyo 1.
Harmonised use of accreditation for assessing the competence of various Conformity Assessment Bodies Dr Andreas Steinhorst, EA ERA workshop 13 April 2016,
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 1 – Free movement of goods Bilateral.
Link between legal framework of VMP regulation and VICH GLs in Japan Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan.
Session 9: The Vision for the Future 1 Dr. Yuko Endo JMAFF.
Session 7: VICH Conference
How to comment VICH guidelines Shixin XU, PhD, Prof. China IVDC.
Slide 1 The contribution of a world-class regulatory environment to the future of the industry in Ireland Pat O’Mahony Chief Executive, Irish Medicines.
An agency of the European Union Consultation on draft VICH guidelines in the EU 2nd VICH Outreach Forum meeting, February 2013 Presented by: Kornelia.
1 THE OIE REPORT 32 nd VICH SC Meeting / 6 th VICH Outreach Forum Meeting Jean-Pierre Orand, Anses, France, OIE Collaborating Centre.
How to get involved in VICH Dr. Allen Bryce Independent consultant Canberra, Australia VICH Workshop: Dar Es Salaam, Tanzania – 24.
Guidance Development Merton V. Smith, Ph.D., J.D. Director International Programs and Product Standards Center for Veterinary Medicine, FDA.
Waiving TABST for vaccines Argentina: Not an allowed procedure today Require batch safety tests in laboratory animals, repeated by authorities Currently.
1 1 Topics “out of the scope of VICH” Brigitte Boenisch IFAH-Europe 2 nd VICH Outreach Forum Meeting Washington, 19 th /20 th February 2012 – how and by.
1 The contribution of VICH to the global One Health approach VICH5 CONFERENCE, OCTOBER 2015, TOKYO Jean-Pierre Orand, Anses, France, OIE Collaborating.
Issues Batch safety testing for vaccines
Update of Results of the Survey on training Priorities
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
Hervé Marion, DVM VICH Secretariat
VICH General Principles and
Commenting on VICH Guidelines in Australia & New Zealand
Nuclear and Treaty Law Section Office of Legal Affairs
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
STRESS TESTS and TAIWAN PEER REVIEW PROCESS
Michelle Limoli, Pharm.D.
Report by the VICH Steering Committee on issues raised by Forum members during the 1st Outreach Forum meeting Hervé Marion, DVM VICH Secretariat.
Nuclear and Treaty Law Section Office of Legal Affairs
Multinational collaboration in the Authorisation of VMPs: the EU approach VICH Outreach Forum Tokyo, Nov 2017 Noel Joseph European Commission.
TAIEX, Istanbul, April 19th, 2011
Waiving Target Animal Batch Safety Testing for vaccines
EU Reference Centres for Animal Welfare
The expectations from VICH Outreach Forum members
Fundamentals of Electronic Submissions and eCTD
The Benefits of VICH to Emerging Countries
Hervé Marion, DVM VICH Secretariat
Presentation transcript:

Session 3: How to use VICH GLs VICH5 Conference, October 2015, Tokyo 1

1.Introduction 2.How are the VICH guidelines used in VICH member and observer countries / regions ? 3.Possible regulatory obstacles and perspectives in adopting VICH guidelines in VICH Outreach Forum countries / regions 1.Introduction 2.How are the VICH guidelines used in VICH member and observer countries / regions ? 3.Possible regulatory obstacles and perspectives in adopting VICH guidelines in VICH Outreach Forum countries / regions 2

Introduction 3

How to use VICH guidelines (1/4) There is wide interest in using VICH guidelines for authorisation of veterinary medicines beyond VICH member, observer and Outreach Forum countries/regions. The use of the VICH guidelines is not restricted to the VICH members, observers or Outreach Forum. Any country or regional organisation can use these guidelines for the requirements for the authorisation of veterinary medicines in their country/region. 4

How to use VICH guidelines (2/4) There are different ways that technical guidelines such as the VICH guidelines can be implemented. It is the decision of the country or region and may depend on how the legislation in the country/region has been set up. The VICH member countries/regions have the obligation to implement the VICH guidelines as adopted by VICH. Observer countries do not have this obligation but implement the VICH guidelines to the fullest extent possible It is encouraged that also other countries using VICH guidelines would use them unchanged. 5

How to use VICH guidelines (3/4) A country/region that was not part of the VICH process developing the guideline may find that it can apply the main part of a VICH guideline, however lacks specific required details or some details are found not suitable due to the specificity of local conditions, e. g. in respect to the specific animal diseases or animal species relevant for that country/region. To benefit from the harmonised guidance in such a case, a VICH guideline can usefully be implemented adapted to fit local conditions. 6

How to use VICH guidelines (4/4) The VICH member countries and regions United States, Japan and EU and the observer country New Zealand will present how they implement VICH guidelines in their country/region The VICH Outreach Forum members ASEAN and CAMEVET will report on possible regulatory obstacles that have been experienced and reflect on perspectives in adopting VICH guidelines in Outreach Forum countries/regions 7

How are VICH guidelines used in the United States ? 8 Dr Merton Smith FDA

How are VICH GLs used in the United States (1/3) Role of Guidelines Guidelines (or Guidances) are documents that explain FDA’s and APHIS’ interpretation of, or policy on, a particular regulatory issue Guidances are prepared primarily for industry, but they also may be useful to other stakeholders as well as to FDA’s or APHIS’ own staff Guidances are used to address such matters as the design, manufacturing, and testing of regulated products; scientific issues; content and evaluation of applications for product approvals; and inspection and enforcement policies 9

Guidance Development Process Industry, consumers and other stakeholders play a very significant role in the guidance development processes After the VICH Expert Working Group produces a draft guidance, the FDA and APHIS invite the public to comment by publication in the Federal Register All submitted comments are considered again by the EWG and addressed when the final guidance is published by FDA and APHIS All guidances are posted on FDA’s and APHIS’ websites and made publicly available in other ways Any interested party can submit comments for consideration even after the guidance has been finalized and implemented 10 How are VICH GLs used in the United States (2/3)

Significance of Guidances in the United States As a VICH Member, the U.S. has committed to using VICH guidances when they are finalized through the VICH consensus process Guidances at FDA or APHIS are not legally binding Guidances describe to stakeholders one way to satisfy a regulatory goal or requirement Stakeholders are free to use other approaches as long as they satisfy relevant U.S. laws and regulations If the VICH guidance that has been adopted by FDA or APHIS as a U.S. guideline requires changes or revisions in the future, the agencies will seek to amend it by again working through the relevant VICH EWG as described above 11 How are VICH GLs used in the United States (3/3)

12 How are VICH guidelines used in Japan? Dr Takashi Kozasa JMAFF

Role of guidelines In Japan JMAFF (HQ and the National Veterinary Assay Laboratory (NVAL)) is responsible for the regulation of veterinary medicinal products (VMPs). In accordance with the legislation (the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc. (Act No. 145 of 1960)), applicants have to submit dossiers including an application form and sets of study data for the approval of VMPs to be sold in Japan. JMAFF issues notices for detailed explanation of the regulations, guidance to application (including technical guidelines), etc. VICH and other technical guidelines are legally non-binding and published as notices from the Director-General of the NVAL. 13 How are VICH GLs used in Japan (1/3)

Role of guidelines (continued) Technical guidelines are fundamental for research & development by applicants and review by regulatory authority. They definitely contribute to expeditious approval of new VMPs. Moreover, harmonized technical guidelines (VICH guidelines) contribute to securing quality, efficacy and safety of VMPs sold in Japan and thus to animal and public health of Japan. 14 How are VICH GLs used in Japan (2/3)

Process Experts from JMAFF, other Ministries and/or academia are involved in the development of the VICH guidelines. Following sign-off of a VICH guideline by the VICH SC at step 3 (for release for consultation), the draft guideline (both English and Japanese versions) is published for public consultation on the government website (for 1 month). Comments received are translated into English and sent to VICH EWG to be considered with all other comments. After finalization of the guideline and sign-off by VICH SC (step 6) a Japanese version of the guideline is published as a notice from the Director-General of the NVAL. The VICH guideline replaces any existing JMAFF guidelines on that topic. 15 How are VICH GLs used in Japan (3/3)

16 How are VICH guidelines used in the European Union? Dr Anja Holm EU - CVMP

Role of guidelines In the EU the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency is responsible for developing technical guidelines The CVMP guidelines give advice on interpretation of regulatory technical requirements and approaches for the assessment of data in respect to marketing authorisation of veterinary medicines and MRLs. Guidelines are prepared primarily for industry applicants, to facilitate the preparation of application dossiers and predictability of applications. to support consistency in interpretation throughout all EU Member States and harmonised implementation 17 How are VICH GLs used in the EU (1/3)

Role of guidelines (contd.) CVMP guidelines are applicable for all VMP applications in the EU independent of responsible authority (all EU Member States and EMA) Legislation (Directive 2001/82/EC and Regulation (EC) No 470/2009) lays down the principle requirements Guidelines are not legally binding but are prepared in support of the legislation Principles above apply equally for VICH guidelines 18 How are VICH GLs used in the EU (2/3)

Process EU experts are involved in the development of the VICH guidelines. Following sign-off of a VICH guideline by the VICH SC at step 3 (for release for consultation), the CVMP adopts the draft guideline at its next meeting (i.e. within 1 month) for public consultation in the EU (6 months). Comments received are sent to VICH EWG and considered with all other comments After finalisation of guidelines and sign-off by VICH SC (step 6) adoption by CVMP and implementation in EU. The VICH guideline will then replace any existing CVMP guideline on that topic 19 How are VICH GLs used in the EU (3/3)

20 How are VICH guidelines used in New Zealand Warren Hughes New Zealand – Ministry for Primary Industries

Role of VICH guidelines Manufacturers/Importers of Veterinary Medicines require guidance on regulatory requirements for the authorisation of veterinary medicines Most Regulators around the world have similar requirements even though the legislation differs New Zealand recognises the value of VICH guidelines in reducing duplication (and resourcing) and provides consistency with other regulatory authorities The VICH process for development of guidance documents is rigorous and draws on international experts to ensure they are robust 21 How are VICH GLs used in New Zealand (1/3)

Process When VICH is developing guidance documents, we (meaning Australia and NZ) provide input into their development MPI utilises VICH guidance documents, where possible, provided they meet our requirements In developing guidance documents (both MPI and/or VICH), MPI undertakes public consultation, which can be targeted or very broad depending on the type of guidance 22 How are VICH GLs used in New Zealand (2/3)

All guidance has to be fit for purpose for the New Zealand situation – each country have unique requirements based on animal/agricultural practices/climate and environment MPI sees value in the VICH guidance documents and have adopted a number of these documents for our requirements The intention is to utilise more of these in the future Our Observer Partner Australia also has a similar position to New Zealand 23 How are VICH GLs used in New Zealand (3/3)

24 Possible regulatory obstacles and perspectives in adopting VICH GLs – ASEAN countries Dr Lim Chee Wee ASEAN representative

Obstacles in adopting VICH guidelines in ASEAN countries (1/2) Diverse legislation and regulatory system in ASEAN countries Limited understanding about VICH Varying levels of technical capability and local conditions in ASEAN countries 25

Efforts in adopting VICH guidelines in ASEAN countries (2/2) ASEAN to maintain participation in VICH Outreach Forum Extend invitation to VICH for ANFPVP Meetings VICH as guidance for development of ASEAN standards -Registration of vaccine -Accreditation of ASEAN animal vaccine testing laboratories 26

27 Possible regulatory obstacles and perspectives in adopting VICH GLs – CAMEVET countries Dr Enrique Argento CAMEVET

Experience in adopting VICH guidelines in CAMEVET countries (1/2) CAMEVET: Regional Organization for harmonization of technical requirements for the Veterinary Products registration. 30 Countries of Americas Region. Official and Private members. Under the Americas OIE Regional Office VICH Guidelines use: Survey Guidelines used How the guidelines are used: original or modified Used as reference or included in the Legal Framework. Advantages and difficulties of VICH GL use. 28

Experience in adopting VICH guidelines in CAMEVET countries (2/2) DIFICULTIES Language Unnecessary and expensive trials for old products. Local or regional differences. Differences in legal framework. ADVANTAGES Easy to retrieve from VICH website. Clear and well based technical information. Information frequently reviewed and updated. Internationally recognized. Facilitates the international harmonization process Used as reference material to develop local or regional new guidelines 29

Perspectives for adopting VICH guidelines The CAMEVET member Countries are not obliged to apply the approved documents and add them in their legislation. All products are considered as new. The Region don´t have a Generic policy. Accepted in countries that import Vet. Products. Some difficulties in countries with local industries or developed legal framework. The VICH Guidelines are used as reference in the mayor part of the CAMEVET Member countries. Many CAMEVET documents are very similar to VICH Guidelines VICH Guidelines could be submitted to CAMEVET as working documents to be approved as Regional recommendation. 30

31 Thank you for your attention! - For discussion -

32 The VICH public website ( 32